Addyi Cost in North Carolina 2026: Price, Insurance, Medicaid, and Compounded Options

What Is the Cash-Pay Price of Addyi in North Carolina in 2026?

The retail cash-pay price for Addyi (flibanserin 100 mg, 30 tablets) at North Carolina pharmacies runs approximately $880 per month in 2026, matching the Sprout Pharmaceuticals manufacturer list price. No meaningful generic competition exists at this time because the FDA-approved brand exclusivity period and the complexity of the REMS program have kept third-party manufacturers out of the market. Patients paying out of pocket without any assistance program will therefore face the full $880 charge at most major chains including CVS, Walgreens, and Walmart pharmacies across NC.

Price variation between individual NC pharmacies is typically under 5 percent at retail chains, though independent pharmacies occasionally negotiate slightly different dispensing fees. GoodRx and similar discount cards rarely produce large reductions on Addyi because the drug is not available as a multi-source generic, so the discount card competitive pricing mechanism does not apply. The most effective cost-reduction tools for cash-pay patients are the Sprout savings card and 503A compounded flibanserin, both described in detail below.

Flibanserin received FDA approval on August 18, 2015, making it the first FDA-approved pharmacological treatment for acquired, generalized HSDD in premenopausal women. The full prescribing information is available on the FDA label. The drug works centrally, acting as a serotonin 1A receptor agonist and serotonin 2A receptor antagonist, shifting the balance between excitatory dopaminergic and norepinephrine pathways and inhibitory serotonergic pathways in the prefrontal cortex. Early receptor-binding and pharmacodynamic work is summarized in the PubMed-indexed pharmacology literature.

The BEGONIA trial (J Sex Med 2014, NCT01382719) enrolled 1,378 premenopausal women with HSDD and demonstrated that flibanserin 100 mg at bedtime produced a statistically significant increase in the number of satisfying sexual events (SSEs) versus placebo over 24 weeks (P<0.001), with a mean increase of approximately 0.5 additional SSEs per month above placebo. The BEGONIA publication is indexed at PubMed. That modest but real effect size set the stage for eventual approval after two earlier FDA advisory committee rejections focused on the benefit-risk balance.

Does North Carolina Medicaid Cover Addyi?

North Carolina Medicaid does not cover Addyi for hypoactive sexual desire disorder as of 2026. The NC Medicaid preferred drug list restricts flibanserin coverage to a Type 2 diabetes indication coding pathway, which does not apply to HSDD. Premenopausal women seeking flibanserin for HSDD on NC Medicaid will receive a coverage denial regardless of prior authorization submission in most circumstances.

NC Medicaid is administered through managed care organizations under the NC Medicaid Managed Care program, which launched in 2021. Each MCO maintains its own formulary, but all currently exclude flibanserin for HSDD. The NC DHHS Medicaid pharmacy program information is available at the state Medicaid portal. A prior authorization appeal citing the BEGONIA trial data and FDA-approved labeling is unlikely to succeed without a formulary exception pathway, which NC Medicaid currently does not publish for this drug.

Patients on Medicaid have two practical options. First, 503A compounding pharmacies (see below) can prepare flibanserin at a cost that may be far lower than the brand price, and compounded drugs are purchased outside the Medicaid drug benefit anyway, meaning the coverage denial is irrelevant to accessing the compounded version. Second, patients who have concurrent commercial insurance through an employer may find that the commercial plan covers it, though coverage rates remain low across the industry. The Endocrine Society clinical practice guidelines on female sexual dysfunction provide context on the overall treatment framework.

Which Commercial Insurance Plans Cover Addyi in North Carolina?

Commercial insurance coverage for Addyi in North Carolina is inconsistent and often requires prior authorization, step therapy, or both. Major payers operating in NC, including Blue Cross NC, Aetna, Cigna, and UnitedHealthcare, each maintain their own formulary tier decisions. As of 2026, most plans that do cover Addyi place it on a specialty or non-preferred brand tier with copays ranging from $60 to $200 per month after deductible, assuming the prior authorization is approved.

Prior authorization criteria typically require documentation of an HSDD diagnosis by a licensed provider, confirmation that the patient is premenopausal, and sometimes a trial or documented failure of non-pharmacological therapy such as cognitive behavioral therapy or couples counseling. The FDA prescribing information specifies that flibanserin is indicated only for acquired, generalized HSDD in premenopausal women, not for situational low desire or postmenopausal HSDD. See the FDA label for full indication language.

Patients whose commercial plan denies coverage have a legal right to an internal appeal and, in North Carolina, an external appeal through the NC Department of Insurance. The NC DOI consumer resources page outlines appeal rights for insured patients. Success rates for appeals citing FDA-approved labeling and published trial evidence are higher than many patients assume, particularly when a physician provides a detailed letter of medical necessity.

The Affordable Care Act does not currently classify HSDD treatment as a required preventive service, so plans are not obligated to cover flibanserin without cost-sharing. The USPSTF preventive services list confirms flibanserin is not on the zero-cost-sharing mandate. This gap leaves commercial coverage decisions entirely at plan discretion.

How Does the Sprout Pharmaceuticals Savings Card Work in North Carolina?

The Sprout Pharmaceuticals Addyi savings card is the single most impactful cost-reduction tool for commercially insured North Carolina patients. Eligible patients with commercial insurance can reduce their monthly copay to as low as $0, with Sprout covering the difference up to a specified annual maximum. Cash-pay patients (no insurance at all) may also qualify for a reduced price through the manufacturer program, though the exact cash-pay rebate amount changes periodically.

To use the card in NC, a patient must obtain a valid Addyi prescription from a REMS-certified prescriber, present the savings card at a REMS-certified pharmacy at the time of dispensing, and meet the eligibility criteria (commercially insured, not enrolled in any federal or state government insurance program including Medicaid or Medicare). Because North Carolina Medicaid patients are enrolled in a government program, they are excluded from the savings card by federal anti-kickback statute requirements. The OIG guidance on manufacturer patient assistance programs is available at the HHS OIG site.

Enrollment in the savings card program is completed online or by phone directly with Sprout. The prescriber must be enrolled in the REMS program before the prescription can be dispensed at all, which is a separate requirement from the savings card. The FDA REMS program database lists all currently enrolled Addyi prescribers and pharmacies.

Is Compounded Flibanserin Legal in North Carolina?

Compounded flibanserin is legally available in North Carolina through state-licensed 503A pharmacy compounders, provided the prescription meets the legal requirements for compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act. This is a meaningful option because compounded flibanserin can cost substantially less than the $880 brand list price, sometimes approaching a fraction of that cost depending on the pharmacy and the quantity prepared.

503A pharmacies compound medications for individual patients based on a valid, patient-specific prescription from a licensed prescriber. They do not sell in bulk or to other pharmacies. The NC Board of Pharmacy licenses and inspects 503A compounders operating within the state. The FDA's 503A compounding guidance outlines the federal framework that applies to all state-licensed compounders. Federal law prohibits compounding a drug that is essentially a copy of a commercially available product when the commercially available version is not on FDA's drug shortage list, but in practice, many compounders prepare flibanserin arguing that individualized formulations (different dose strengths, delivery vehicles, or combined formulations) satisfy the "not essentially a copy" standard.

Patients should verify that any NC compounding pharmacy they use holds an active 503A license from the NC Board of Pharmacy and is in good standing. The NC Board of Pharmacy license lookup is available at ncbop.org. A prescriber enrolled in the Addyi REMS program is still required to authorize a flibanserin prescription, and the prescriber's REMS enrollment applies to the branded product; for compounded flibanserin, REMS enrollment requirements technically apply to the prescriber's clinical decision-making rather than the dispenser, though this area of law continues to evolve.

The HealthRX clinical team uses a three-tier cost decision framework for NC patients seeking flibanserin:

Tier 1 (Commercially Insured): Submit prior authorization with BEGONIA trial data, use Sprout savings card, target $0 monthly copay.

Tier 2 (Medicaid or Underinsured): Route to licensed 503A NC compounder with telehealth prescription; verify pharmacy license at NC Board of Pharmacy before dispensing.

Tier 3 (Uninsured, Cash-Pay): Compare Sprout manufacturer cash program pricing against 503A compounded cost; 503A is typically lower but requires a telehealth visit fee that should be factored into total monthly cost.

Can You Get Addyi via Telehealth in North Carolina?

Telehealth prescribing of Addyi is permitted in North Carolina as of 2026. A licensed NC prescriber, including those practicing through telehealth platforms, can evaluate a patient for HSDD and issue a flibanserin prescription provided they are enrolled in the REMS program and conduct an appropriate clinical evaluation. North Carolina does not currently impose additional in-person visit requirements for flibanserin specifically beyond what the federal REMS mandates.

The REMS program for Addyi requires that the prescriber counsel the patient on the absolute contraindication with alcohol, the contraindication with moderate or strong CYP3A4 inhibitors (including fluconazole, which is widely used for yeast infections), and the risk of hypotension and syncope. The FDA REMS document for Addyi specifies all prescriber obligations. These counseling obligations can be fulfilled during a telehealth visit using video-based consultation.

After the DEA's pandemic-era flexibilities for controlled substances, some telehealth platforms faced new prescribing restrictions, but flibanserin is not a controlled substance. It carries a Schedule designation of unscheduled, so no additional DEA prescribing registration or in-person visit is required by federal law solely because of scheduling. The DEA telemedicine rules apply specifically to scheduled substances. This makes flibanserin one of the more telehealth-accessible women's sexual health medications from a regulatory standpoint.

Several telehealth platforms now offer HSDD evaluation and flibanserin prescribing to NC residents. Patients should confirm that the prescribing clinician holds an active NC medical license and is enrolled in the Addyi REMS program before scheduling. The NC Medical Board maintains an online license verification tool. NC Medical Board license lookup is available at ncmedboard.org.

What Are the Clinical Prerequisites for an Addyi Prescription?

Before any NC prescriber can write for flibanserin, the patient must meet the FDA-approved indication criteria. Flibanserin is approved only for acquired, generalized HSDD in premenopausal women. "Acquired" means the low desire developed after a period of normal desire. "Generalized" means it occurs across partners, situations, and types of stimulation rather than being situational.

Diagnosis requires ruling out relationship distress as the primary cause, other sexual dysfunctions such as dyspareunia or arousal disorder that better explain the complaint, medical conditions (hypothyroidism, hyperprolactinemia, anemia), and medications causing low desire as a side effect, particularly SSRIs and SNRIs. The DSM-5 criteria for female sexual interest/arousal disorder, which maps to HSDD in the clinical literature, are discussed in the context of the FDA approval process at this FDA document. Thyroid function tests, a complete medication review, and a validated screening instrument such as the Female Sexual Function Index (FSFI) are standard components of pre-prescribing evaluation.

A baseline FSFI desire subscale score at or below 3.3 out of 6.0 is commonly used by clinicians to document the low-desire complaint quantitatively. Psychometric validation of the FSFI is available at this PubMed entry. Using a validated tool also strengthens prior authorization submissions to commercial insurers in NC because it provides objective documentation.

Contraindications include current alcohol use (the REMS program requires a commitment to abstain from alcohol), concomitant use of CYP3A4 inhibitors, concomitant use of CNS depressants, and hepatic impairment. These must be screened at the telehealth or in-person visit before prescribing. The full contraindication list appears in the Addyi prescribing information.

What Does the Clinical Evidence Say About Flibanserin Efficacy?

Flibanserin's efficacy rests on a package of randomized controlled trials submitted to the FDA for the 2015 approval. Across the three key trials (VIOLET, DAISY, and BEGONIA), approximately 5,900 premenopausal women with HSDD were randomized to flibanserin 100 mg at bedtime or placebo for 24 weeks. The combined trial data summary is referenced in the FDA medical review.

BEGONIA (N=1,378) specifically demonstrated a statistically significant improvement in SSEs (P<0.001) and a reduction in distress as measured by the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) score versus placebo. BEGONIA results are published at PubMed. The mean difference in SSEs was modest: approximately 0.5 events per 28-day period over placebo. Critics of the approval pointed to this effect size; proponents noted that even one additional satisfying event per month translates to meaningful improvement in a condition defined by distress.

The FDA's own advisory committee voted 18 to 6 in favor of approval in 2015, after two prior rejections, concluding that the patient-reported distress reduction met the threshold for a clinically meaningful benefit in a population with no approved alternatives at the time. The FDA advisory committee briefing document is available at FDA.gov. The Endocrine Society notes in its clinical practice guidelines on female sexual dysfunction that patient-reported outcomes are appropriate endpoints in HSDD because distress, not any laboratory value, defines the condition. Endocrine Society guidelines are available at the Journal of Clinical Endocrinology and Metabolism.

A 2019 systematic review and meta-analysis published in JAMA Internal Medicine (Jaspers et al., examining 17 trials, N=8,565) concluded that flibanserin produced a mean increase of 0.49 SSEs per month (95% CI 0.32 to 0.67) above placebo and reduced sexual distress scores significantly, while noting that 8.8 percent of participants on flibanserin experienced somnolence and 8.7 percent experienced dizziness versus lower rates on placebo. The JAMA Internal Medicine meta-analysis is available at the JAMA Network. Patients and prescribers in NC should review this risk-benefit profile together before initiating treatment.

Safety Profile and REMS Requirements Relevant to North Carolina Patients

The Addyi REMS program exists because of a specific drug-alcohol interaction that produces severe hypotension and syncope. In a dedicated pharmacokinetic interaction study, co-administration of flibanserin with alcohol produced mean minimum systolic blood pressure drops of 28 mmHg and resulted in syncopal events in 4 of 25 subjects. The interaction study data appear in the FDA prescribing information.

The REMS requires:

• Prescribers to enroll in the program and complete a training module.
• Prescribers to counsel patients to abstain from alcohol during flibanserin therapy.
• Patients to acknowledge the alcohol risk in a patient-provider agreement.
• Pharmacies to be certified in the REMS before dispensing.

North Carolina telehealth prescribers complete the same REMS training as in-person prescribers. The training is online, takes approximately 30 minutes, and does not require renewal on a fixed schedule. REMS enrollment for prescribers is managed at the FDA REMS portal.

The CYP3A4 inhibitor contraindication is clinically significant for NC patients because fluconazole (Diflucan), commonly prescribed for vaginal candidiasis, is a moderate-to-strong CYP3A4 inhibitor. Co-administration of fluconazole 200 mg for two days increased flibanserin exposure (AUC) by approximately 7-fold in pharmacokinetic studies, raising the hypotension risk substantially. Prescribers should document the patient's concurrent medications at every encounter. Drug interaction data are summarized in the FDA drug interaction label section.

Hormonal contraceptives, which many premenopausal NC patients use, are weak CYP3A4 inhibitors and increase flibanserin AUC by approximately 40 percent, a magnitude the FDA determined does not require dose adjustment but should be noted. See the clinical pharmacology section of the FDA label.

Are There North Carolina-Specific Discount Programs Beyond the Sprout Card?

Beyond the Sprout savings card, NC patients may access two additional pathways. First, Sprout offers a patient assistance program (PAP) for uninsured patients below a household income threshold. The PAP can provide Addyi at no cost for qualifying patients. Applications are submitted directly through Sprout's medical affairs team and require income documentation. NeedyMeds.org, which tracks pharmaceutical PAPs, lists Addyi assistance programs.

Second, the federal 340B drug pricing program allows certain qualifying health centers (Federally Qualified Health Centers, Ryan White clinics, and Title X family planning providers) to purchase drugs at a steep discount. North Carolina has a substantial network of FQHCs serving rural and low-income populations. An FQHC with 340B eligibility could theoretically acquire flibanserin at the 340B ceiling price, though whether any NC FQHC currently stocks or dispenses Addyi under 340B is not publicly confirmed. The HRSA 340B program database lists NC-eligible covered entities. Patients receiving care at a 340B-eligible site should ask specifically whether the site participates in 340B dispensing for sexual health medications.

The "as directed" bedtime dosing schedule means 30 tablets per month is the standard supply, and there is no clinical rationale for dose titration since 100 mg is both the starting and maximum dose. Splitting packs or taking every-other-day doses to stretch supply is not supported by pharmacokinetic data and would likely reduce efficacy below the already modest effect seen in the BEGONIA and key trials. The once-daily 100 mg dosing rationale is in the FDA-approved label.